| ²é¿´: 1384 | »Ø¸´: 3 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
zhangchong2303½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
°¢Âå·ò¶¨£¨alovudine£©ÐÂÒ©ÁÙ´²¼¸ÆÚ£¿
|
||
|
ÇóÖú¸÷λ´óÏÀ£¬ÎÒÏë²éѯһϰ¢Âå·ò¶¨£¨alovudine£©ÐÂÒ©ÁÙ´²µ½¼¸ÆÚ¡£Ò»ÏÂÎÒÊÇÃÀ¹úµÄclinicaltrialÉÏÃæ²éµ½µÄÐÅÏ¢£¬¿´²»¶®ÊǼ¸ÆÚÔõôÅжϡ£ Found 14 studies with search of: Alovudine Hide studies that are not seeking new volunteers. Hide studies with unknown recruitment status. Display Options Rank Status Study 1 Completed An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects Condition: HIV Infections Intervention: Drug: Alovudine 2 Completed An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects Condition: HIV Infections Intervention: Drug: Alovudine 3 Completed A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC) Condition: HIV Infections Intervention: Drug: Alovudine 4 Recruiting Monitor Response to Treatment in Neuroblastoma Using 3'-Deoxy-3'-Fluorothymidine- Positron Emission Tomography (FLT-PET) Condition: Neuroblastoma Intervention: Device: FLT-PET 5 Recruiting Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) Conditions: High-grade Glioma; Astrocytoma; Glioblastoma Intervention: Radiation: 18F Fluorothymidine PET CT 6 Recruiting Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors Condition: Breast Cancer Interventions: Drug: BMS-754807; Drug: letrozole 7 Recruiting A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma Conditions: Cancer; Solid Tumor; Lymphoma Intervention: Biological: 18F-FLT 8 Recruiting Image-Guided Stereotactic Biopsy of High Grade Gliomas Conditions: Brain Cancer; Glioma Intervention: Procedure: 18F-FLT PET Scan 9 Completed 18F-FLT-PET in Breast Cancer (MK-0000-139 AM1) Condition: Breast Cancer Intervention: Procedure: 18F-FLT-Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging 10 Recruiting Pilot Study of 18F-FLT PET Conditions: CNS Brain Metastasis; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Esophageal Cancer Intervention: Procedure: Imaging with 18F-FLT PET 11 Terminated A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors Condition: Tumors of the Central Nervous System Intervention: Other: [18F]-Fluorothymidine 12 Recruiting An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine Condition: Pancreatic Cancer Intervention: Procedure: Positron-Emission Tomography (PET) 18F-FLT 13 Recruiting Validation of 18F-MISO-PET and 18F-FLT-PET Condition: Head and Neck Neoplasms Intervention: Procedure: 18F-FLT and 18F-MISO-PET 14 Recruiting Clinical Application of 18F-3'-Fluoro-3'-Deoxy-L-thymidine (18F-FLT) Positron Emission Tomography (PET) in Lung Tumors Condition: Lung Cancer Intervention: Çó½âÊÍ£¬·Ç³£¸Ðл |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÐÂÒ©·¢ÏÖ |
» ²ÂÄãϲ»¶
TCEÒ©ÎïÖÎÁÆÖ×Áö²¡È˺óÃâÒßϸ°ûÖØ½¨µÄ¼ì²â
ÒѾÓÐ18È˻ظ´
ÊDz»ÊÇÏÖÔÚ¿¼²©¶¼ÊÇÍÆ¼öÖÆ£¿»òÕßÊÇÒѾÄÚ¶¨ÁË£¿»¹ÓÐͨ¹ý¿¼ÊÔÕв©Ê¿µÄѧУÂð£¿
ÒѾÓÐ39È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ156È˻ظ´
Å©²úÆ·ÖÐũҩ¼à²âµÄÃâÒß´«¸ÐÆ÷µÄÒÉÎÊ
ÒѾÓÐ0È˻ظ´
ÄÉÃ×´«¸ÐÆ÷¼à²âũҩ²ÐÁôµÄÒÉ»ó
ÒѾÓÐ0È˻ظ´
ËÓÐÈËÎÀ°æ ¡¶¶¾Àíѧ»ù´¡¡·µÚÆß°æÊé¼®
ÒѾÓÐ0È˻ظ´
26ÓÐûÓÐÀÏʦÏëÊÕ×ö¶¨Á¿Ò©ÀíµÄѧÉú°¡
ÒѾÓÐ3È˻ظ´
26¿¼²©ÉêÇë ѧorר
ÒѾÓÐ15È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Nat Biotech£º2003-2011ÄêÐÂÒ©ÁÙ´²Ñо¿³É¹¦ÂÊ·ÖÎö±¨¸æ
ÒѾÓÐ6È˻ظ´
¹úÍâÐÂÒ©£¬ÒѾ½øÈë¢òÆÚÁÙ´²Ñо¿µÄÐÂÒ©½øÕ¹Çé¿öÈçºÎ²éѯ£¿£¿£¿
ÒѾÓÐ6È˻ظ´
ÖÐÒ©ÐÂÒ©ÁÙ´²Ç°Ñо¿Ò©Ñ§Ñо¿×ÊÁÏҪעÒâʲô²ÅÄÜÌá¸ßͨ¹ýÂÊ
ÒѾÓÐ3È˻ظ´
É걨ÖÐÒ©ÐÂÒ©ÁÙ´²Åú¼þµ½Ê¡¾ÖʱµÄÏÖ³¡¿¼ºËҪעÒâʲô£¿
ÒѾÓÐ4È˻ظ´
ÉêÇëÐÂÒ©ÁÙ´²£¬ÒÑ·¢Åú¼þ£¬ÊÇ·ñ¾ÍÊDZ»Åú×¼ÁÙ´²£¿
ÒѾÓÐ10È˻ظ´
ÈýÆÚÁÙ´²£¬ÕæµÄºÜÄÑ
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿ÇëÎÊÐÂÒ©ÁÙ´²ÊÔÑéµÄÉ걨×ÊÁÏÔÚÄÄÀï¿ÉÒԲ鵽°¡£¿
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÖÐÒ©ÐÂÒ©ÁÙ´²Ñо¿Ö¸µ¼ÔÔòµÚ¶þ¼ 1993°æ
ÒѾÓÐ12È˻ظ´
¡¾ÇóÖú¡¿ÐÂÒ©ÁÙ´²Ç°Ñо¿°üÀ¨ÄÇЩÄÚÈÝ
ÒѾÓÐ6È˻ظ´
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24579.6
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.3Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
4Â¥2012-02-02 13:53:25
nkbeholder
ľ³æ (ÕýʽдÊÖ)
- DRDEPI: 1
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 2945.1
- É¢½ð: 4
- ºì»¨: 5
- Ìû×Ó: 748
- ÔÚÏß: 303.7Сʱ
- ³æºÅ: 202353
- ×¢²á: 2006-03-01
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
lk590(½ð±Ò+1): лл²ÎÓë 2012-02-02 11:31:54
zhangchong2303(½ð±Ò+10): ¡ï¡ï¡ïºÜÓаïÖú лл£¬´ÓÕâÉÏÃæ¿´Ó¦¸ÃÊÇÁÙ´²2ÆÚ£¬ÊÇÂ𣿠2012-02-02 13:47:37
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
lk590(½ð±Ò+1): лл²ÎÓë 2012-02-02 11:31:54
zhangchong2303(½ð±Ò+10): ¡ï¡ï¡ïºÜÓаïÖú лл£¬´ÓÕâÉÏÃæ¿´Ó¦¸ÃÊÇÁÙ´²2ÆÚ£¬ÊÇÂ𣿠2012-02-02 13:47:37
|
dialogÉϵÄÐÅÏ¢£¬¸üе½2007Äê Originator Company: Medivir AB (Sweden) Parent Company: Medivir AB Licensee: Beijing Mefuvir Medicinal Technology Highest Phase: Discontinued II Development Status: Discontinued II, France, HIV infections treatment Discontinued II, Sweden, HIV infections treatment Discontinued II, USA, HIV infections treatment |
2Â¥2012-02-02 11:28:31
nkbeholder
ľ³æ (ÕýʽдÊÖ)
- DRDEPI: 1
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 2945.1
- É¢½ð: 4
- ºì»¨: 5
- Ìû×Ó: 748
- ÔÚÏß: 303.7Сʱ
- ³æºÅ: 202353
- ×¢²á: 2006-03-01
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
3Â¥2012-02-02 13:49:56













»Ø¸´´ËÂ¥